1 Green Flag for AbbVie (ABBV) Stock Right Now

Core Insights - AbbVie is a strong candidate for long-term investment due to its robust dividend yield of 3.1%, significantly higher than the S&P 500's yield of 1.2% [1] - The company has demonstrated consistent dividend growth, with an average annual increase of 7% over the past five years [2] Dividend Performance - AbbVie's total annual payout recently reached $6.56 per share, up from $5.20 in 2021 and $3.59 in 2018, indicating substantial growth [2] - The payout ratio is less than 50%, suggesting ample room for future dividend increases [4] Pipeline and R&D Investment - AbbVie has around 90 treatments in its pipeline, having invested nearly $11 billion in research and development in 2024 [5] - The majority of these treatments are in the mid to late stages of development, positioning the company for future growth despite past patent losses [5] Stock Performance and Valuation - AbbVie's stock has averaged annual gains of 15.8% over the past decade, indicating a promising future [6] - The current forward-looking price-to-earnings (P/E) ratio is 15, above the five-year average of approximately 12, suggesting that shares may not be a bargain at this time [6]